ABT-333: Phase III started

Abbott, which markets Norvir ritonavir, has exclusive rights to ABT-450, an oral HCV NS3/4A protease inhibitor, from Enanta Pharmaceuticals Inc. (Cambridge, Mass.) (see BioCentury, Dec. 18, 2006). ...